Simple blood test could spot colon cancer early
NCT ID NCT07168876
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is testing a new blood test called Delta-HLD to see how well it can detect colorectal cancer in average-risk people aged 45-75. About 3,200 participants will give a blood sample before their scheduled screening colonoscopy, which will be used as the gold standard for comparison. The goal is to see if this liquid biopsy can accurately identify cancer and advanced precancerous growths.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Delta-HLD liquid biopsy test
What this could lead to
If successful, this could provide a simpler, less invasive blood test for colorectal cancer screening, potentially increasing screening rates.
What could go wrong
This is an early validation study, not a treatment trial. The test may not be accurate enough to replace colonoscopy, and results may not apply to higher-risk groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Epiliquid
RECRUITINGMendoza, Mendoza Province, 5500, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••